According to MedImmune, the AstraZeneca subsidiary that makes FluMist, studies have shown that people ages 18 to 49 can successfully give the vaccine, and it's just as effective as having a doctor ...
Alchemab’s new CEO is the company’s co-founder and hitherto CSO, Jane Osbourn.
In other H5N1 developments, the FDA's vaccine advisory group said it will discuss the composition of H5 vaccines when it ...
The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...
( MENAFN - PR Newswire) NEW YORK, Sept. 23, 2024 /PRNewswire/ -- MTS health Partners ("MTS") announced today that healthcare investment banker Aaron Schwimmer has joined their global life sciences ...
The Minnesota Department of Health has reported two variant H3N2 (H3N2v) flu infections, both involving young people who ...